Compare Mesoblast Limited (MESO) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs United Microelectronics Corp — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while United Microelectronics Corp trades at $21.15 (market cap $51.00B). The key difference: United Microelectronics Corp is far larger — about 23.5× Mesoblast Limited's market cap, and United Microelectronics Corp pays a 2.03% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | UMC | |
|---|---|---|
Market Cap | $2.17B | $51.00B |
Sector | Technology | Technology |
52-Week High | $20.96 | $28.02 |
52-Week Low | $12.88 | $6.58 |
Enterprise Value | $2.17B | $48.57B |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
UMC trades at $20.41, down 3.95% for the day, with a bearish technical signal but oversold RSI readings. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains strong profitability with a 20.25% net margin. Recent news highlights mass production of silicon photonics ICs and a new 14nm eHV platform, signaling innovation in semiconductor technology.
Outlook is mixed: analyst consensus leans Hold (53%) amid high valuation multiples (P/E 34.5), but earnings beats and specialty tech growth offer upside. Risks include competitive pressures and margin compression from 32.1% in 2022 to 17.0% in 2025. Cash flow improved to $5.66B net in 2025, supporting dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
